ADAM17 Antibody

Code CSB-PA050200
Size US$167
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P78536
Target Names ADAM17
Alternative Names A disintegrin and metalloproteinase domain 17 (tumor necrosis factor; alpha; converting enzyme) antibody; A disintegrin and metalloproteinase domain 17 antibody; ADA17_HUMAN antibody; ADAM 17 antibody; ADAM metallopeptidase domain 17 antibody; ADAM17 antibody; ADAM17 protein antibody; CD 156b antibody; CD156b antibody; CD156b antigen antibody; CSVP antibody; Disintegrin and metalloproteinase domain-containing protein 17 antibody; MGC71942 antibody; NISBD antibody; NISBD1 antibody; Snake venom like protease antibody; Snake venom-like protease antibody; TACE antibody; TNF alpha convertase antibody; TNF alpha converting enzyme antibody; TNF-alpha convertase antibody; TNF-alpha-converting enzyme antibody; Tumor Necrosis Factor Alpha Converting Enzyme antibody
Raised in Rabbit
Species Reactivity Human,Mouse,Rat
Immunogen Synthesized peptide derived from Human TACE around the non-phosphorylation site of T735.
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form Liquid
Tested Applications IF, ELISA
Recommended Dilution
Application Recommended Dilution
IF 1:200-1:1000
ELISA 1:5000
Protocols Immunofluorescence (IF) Protocol
ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2.
Gene References into Functions
  1. High ADAM17 expression is associated with cystic fibrosis. PMID: 29351448
  2. These findings link iNOS to Notch1 signaling in CD24(+)CD133(+) LCSCs through the activation of TACE/ADAM17. PMID: 30297396
  3. ADAM17 activation and secretion in the myeloid cells during HIV infection. PMID: 29331674
  4. A novel ADAM17 inhibitor ZLDI-8 may be a potential chemosensitizer which sensitized CRC cells to 5-fluorouracil or irinotecan by reversing Notch and EMT pathways. PMID: 30069943
  5. The isolated membrane proximal domain (MPD) of ADAM17 binds to phosphatidylserine (PS) but not to phosphatidylcholine liposomes. A cationic PS-binding motif is identified in this domain, replacement of which abrogates liposome-binding and renders the protease incapable of cleaving its substrates in cells. PMID: 27161080
  6. ADAM-17 in inflammatory myopathy was significantly higher than that in healthy control. ADAM-17 in post-treatment with corticosteroid and/or immunosuppressant serum was significantly decreased compared with that in pre-treatment serum. PMID: 29411180
  7. The present research suggests that ADAM17shRNA can inhibit MCF7 cell invasion and proliferation in vitro and inhibit MCF7 xenograft growth in vivo through the EGFR/PI3K/AKT and EGFR/MEK/ERK signaling pathways. PMID: 29393483
  8. Uev1A-Ubc13 complex catalyzes lysine63-linked ubiquitination of RHBDF2 to promote TACE maturation. PMID: 29069608
  9. ADAM17 plays a role in chronic kidney disease-mineral and bone disorder. PMID: 29056164
  10. Insulin-like growth factor-1 activates different catalytic subunits p110 of PI3K in a cell-type-dependent manner to induce lipogenesis-dependent epithelial-mesenchymal transition through the regulation of ADAM10 and ADAM17. PMID: 28819788
  11. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157. Findings reveal a link between shedding of TREM2 and its regulation during inflammatory conditions or chronic neurodegenerative disease in which activity or expression of sheddases might be altered. PMID: 28923481
  12. Oxidative stress is correlated with hyperactivation of the ADAM17/Notch signaling pathway and a consequent increase in fibrosis in patients with endometriosis. PMID: 28486700
  13. Plasma levels of ADAM17 are increased in Tanzanian children hospitalized with a malaria infection compared with asymptomatic children but similar to children hospitalized with other infectious diseases. The plasma levels of ADAM17 decreased during recovery after an acute malaria episode. PMID: 27784899
  14. Data found that ADAM17 is constitutively internalized by clathrin-coated pits and that physiological stimulators such as GPCR ligands induce ADAM17-mediated shedding, but do not alter the cell-surface abundance of the protease. Also, physiological activation of ADAM17 does not rely on its relocalisation, but that PMA-induced PKC activity drastically dysregulates the localisation of ADAM17. PMID: 27731361
  15. Cullin 3 regulates ADAM17-mediated ectodomain shedding of AREG. PMID: 29550478
  16. ADAM17 may be a key enzyme that regulates the generation of TNF-alpha in oral keratinocytes. PMID: 28637950
  17. therapies against ADAM10 and ADAM17 may promote cancer stem cell migration away from the tumourigenic niche resulting in a differentiated phenotype that is more susceptible to treatment. PMID: 27541285
  18. ADAM10 and ADAM17 are the best characterized members of the ADAM (A Disintegrin and Metalloproteinase) - family of transmembrane proteases. Both are involved diverse physiological and pathophysiological processes.For ADAM17 phosphatidylserine exposure is required to then induce its shedding function. PMID: 28624437
  19. In the present study, the authors show that deletion of a triple serine (3S) motif (Ser-359 to Ser-361) adjacent to the cleavage site is sufficient to prevent IL-6R cleavage by ADAM17, but not ADAM10. We find that the impaired shedding is caused by the reduced distance between the cleavage site and the plasma membrane. PMID: 27151651
  20. ADAM17 is a Western diet-inducible enzyme activated by CXCL12-CXCR4 signaling, suggesting the pathway: Western diet-->CXCL12-->CXCR4-->ADAM17-->TGFalpha-->EGFR. ADAM17 might serve as a druggable target in chemoprevention strategies PMID: 27489286
  21. The regulation of the shedding activity of ADAM17 is multilayered and different regions of the protease are involved. Intriguingly, its extracellular domains play crucial roles in different regulatory mechanisms. We will discuss the role of these domains in the control of ADAM17 activity. PMID: 28571693
  22. We show ADAM17 expression in human dopaminergic neurons derived from induced pluripotent stem cells and we discuss how this state-of-the-art technology can be further exploited to study the function of this important protease in the brain and other tissues. PMID: 28705384
  23. High ADAM17 expression is associated with radioresistance in liver cancer. PMID: 26993601
  24. inhibition of autophagy led to the decrease in stemness, restoration of mitochondrial proteins and reduced expression of CD44, ABCB1 and ADAM17 PMID: 29171106
  25. FoxM1 regulates the expression of ADAM-17, which is upregulated in gastric carcinoma. PMID: 29180185
  26. Glypican-1 was validated as a novel substrate for ADAM17, with important function in adhesion, proliferation and migration of carcinoma cells. PMID: 27576135
  27. the chaperone 78-kDa glucose-regulated protein (GRP78) protects the MPD against PDI-dependent disulfide-bond isomerization by binding to this domain and, thereby, preventing ADAM17 inhibition. PMID: 28949004
  28. The ADAM17 messenger RNA (mRNA) and protein levels were significantly higher in the inferior turbinate than in nasal polyps (p < 0.05). The ADAM10 mRNA and protein levels did not differ significantly between NPs and inferior turbinates (p > 0.05). ADAM10 and ADAM17 were expressed primarily in inflammatory cells, submucosal glandular cells, and lining epithelial cells. PMID: 27012683
  29. The iRhom2 N-terminus stabilizes mature ADAM17 at the cell surface where it cleaves TNF and EGFR in inflammatory and innate immune responses. (Review) PMID: 28815577
  30. inhibition of ADAM17 enhanced the purity of expanded NK cells and the antibody-dependent cellular cytotoxicity activity of these cells against trastuzumab treated breast cancer cell lines. PMID: 28982863
  31. hypoxia instigates the RSK1-dependent C/EBPbeta signaling pathway, which in turn initiates binding of C/EBPbeta to the ADAM 17 promoter and ultimately induces ADAM 17 expression in human lung fibroblasts. PMID: 28646679
  32. TNF-alpha-converting enzyme -mediated cleavage of soluble RANKL from activated lymphocytes, especially B cells, can promote osteoclastogenesis in periodontitis. PMID: 27815441
  33. Cell stimulation can downregulate expression of mature ADAM17 from the cell surface and induce release of exosomal ADAM17, which can then distribute and contribute to substrate shedding on more distant cells. PMID: 27599715
  34. Aging and obesity cooperatively reduce caveolin-1 expression and increase vascular endothelial ADAM17 activity and soluble TNF release in adipose tissue, which may contribute to the development of remote coronary microvascular dysfunction in older obese patients. PMID: 28473444
  35. Our data demonstrated that elevated serum Semaphorin5A (Sema5A) in SLE patients correlated with disease activity and are involved in kidney and blood system damage; ADAM17 might be involved in the release of secreted Sema5A. PMID: 28063160
  36. ADAM17 and ADAM10 cleave Nectin-4 and release soluble Nectin-4 (sN4). PMID: 28232483
  37. ADAM17 promotes epithelial-mesenchymal transition via the TGF-beta/Smad pathway. the present study demonstrates that ADAM17 plays a critical role in the development of gastric cancer and provides a potential therapeutic target for gastric cancer. PMID: 27779657
  38. FHL2 interacts with ADAM-17 in normal, dysplastic and malignant colon epithelial cells. Colocalisation of these proteins is more frequent in malignant than in normal and dysplastic cells, suggesting a role for ADAM-17/FHL2 complex in the development of colorectal cancer. PMID: 28349819
  39. The present study suggests that ADAM17-siRNA inhibits MCF-7 breast cancer and is activated through the EGFR-PI3K-AKT signaling pathway PMID: 27221510
  40. Data show that mononuclear leukocytes (PBMC) AXL receptor tyrosine kinase (Axl) is rescued by combined matrix metalloproteases ADAM10 and TACE (ADAM17) inhibition. PMID: 27237127
  41. the TLR4/Gal-1 signaling pathway regulates lactate-mediated EMT processes through the activation of ADAM10 and ADAM17 in colon cancer cells. PMID: 27837433
  42. The HNE-TACE signalling pathway has an important role in the process of MUC5AC overexpression in chronic rhinosinusitis. PMID: 26881964
  43. The inhibition of cell proliferation and invasion was observed in the ADAM17 knockdown cells, which was associated with modulation of the EGFR signalling pathway. PMID: 27878499
  44. ADAM17 expression was increased in the sepsis patients with the rs12692386 GA/GG genotypes, accompanied by up-regulation of expression of the ADAM17 substrates (TNF-alpha, IL-6R and CX3CL1) and pro-inflammatory cytokines (IL-1beta and IL-6). PMID: 27607600
  45. ADAM17 genetic variants were shown to be associated with KD risk, even when excluding the influence of TGF-beta signaling pathway genes, suggesting that ADAM17 is an important KD susceptibility-related genetic locus. PMID: 26833052
  46. We found that percent body fat was directly associated with TLR4 and TACE expression in skeletal muscle of older adults. PMID: 26988770
  47. Presented genes, especially ADAM17, MMP9, EphA2, TIMP1, ICAM 11, and CD4, may be used as prognostic markers of advanced stages of colorectal cancer, contributing to the development of new lines of therapy focused on reducing metastasis of the primary tumor. PMID: 27110571
  48. We also demonstrated that the cell-surface CA IX level dropped during the death progress due to an increased ECD shedding, which required a functional ADAM17. Inhibitors of metalloproteinases reduced CA IX ECD shedding, but not apoptosis. PMID: 26993100
  49. Case Report: genetic deficiency of ADAM17 altering cytokine secretion and NK cell activity. PMID: 26683521
  50. lower expression levels in the allergic nasal mucosa PMID: 26250527
  51. The production of ADAM17-positive microvesicless from smoke-exposed neutrophils provides a novel molecular mechanism for the vastly accelerated risk of AAA in smokers. PMID: 26422658
  52. miR-338-3p is significantly decreased in gastric cancer, and inhibits cell proliferation, migration and invasion partially via the downregulation of ADAM17. PMID: 26617808
  53. results explain how loss of the amino terminus in iRhom1 and iRhom2 impairs TNF signaling, despite enhancing ADAM17 activity PMID: 26535007
  54. Estrogen upregulates MICA/B expression in human non-small cell lung cancer through the regulation of ADAM17. PMID: 25363527
  55. The effects of ADAM17 inhibition on the cancer stem cells phenotype and chemosensitivity to 5-fluorouracil (5-FU) in colorectal cancer cells were examined. siRNA knockdown and TAPI-2 decreased the protein levels of cleaved Notch1 PMID: 26744411
  56. Data indicate a potent and specific ADAM metallopeptidase domain 17 (ADAM17) inhibitory antibody, MEDI3622, which induces tumor regression or stasis in many epidermal growth factor receptor (EGFR)-dependent tumor models. PMID: 25948294
  57. ADAM17 is important for the migratory potential of immortalized human dermal lymphatic endothelial cells. PMID: 26176220
  58. High ADAM17 expression was associated with lymph node metastasis, vascular invasion, the presence of recurrence in patients with gastric cancer who underwent curative gastrectomy. PMID: 25786367
  59. N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domain. PMID: 25387128
  60. Adam17, a target of Mir-326, promotes epithelial-mesenchymal transition-induced cells invasion in lung adenocarcinoma. PMID: 26111641
  61. analysis of dose-dependent heterogeneity in PMA-mediated ADAM17 activation in a microfluidic assay PMID: 25832727
  62. Patients with HBeAg-positive CHB have aberrant demethylation of the TACE promoter, which may potentially serve as a biomarker for HBeAg seroconversion. PMID: 26217090
  63. our data suggest that the anti-inflammatory actions of paricalcitol in tubular cells could depend on the inhibition of TGF-a/ADAM17/EGFR pathway in response to aldosterone, showing an important mechanism of VDRAs action. PMID: 26064952
  64. miR-634 mimics induced a proinflammatory phenotype in monocyte-derived macrophages, with enhanced expression and release of ADAM17 and IL-6 in Proteinase-3 ANCA-Associated Vasculitis PMID: 25788529
  65. established that endogenous IL-6R of both human and murine origin is shed by ADAM17 in an induced manner, whereas constitutive release of endogenous IL-6R is largely mediated by ADAM10 PMID: 26359498
  66. ADAM17 protein was highly expressed in esophageal squamous cell carcinoma. PMID: 25966212
  67. Knockdown of ADAM17 elicited similar effects to that of miR-145 on NPC cells. PMID: 26297956
  68. EGFR-mediated activation of the downstream effectors ERK1/2 in pSS SGEC appeared to require ADAM17-dependent release of the endogenous EGFR ligand amphiregulin and transactivation of the EGFR. PMID: 24664458
  69. The extracellular juxtamembrane segment of ADAM17, besides being involved in substrate recognition, is able to interact with lipid bilayers in vitro and this property could be involved in regulating ADAM17 shedding activity. PMID: 26348730
  70. A score including ADAM17 substrates predicts recurring cardiovascular event in subjects with atherosclerosis. PMID: 25687272
  71. Results strongly suggest that TACE contributes to the development of psoriatic lesions through releasing two kinds of psoriasis mediators, TNF-a and EGFR ligands. PMID: 25384035
  72. This study identifies TACE as an essential player in OL regeneration that may provide new insights in the development of new strategies for promoting myelin repair in demyelinating disorders. PMID: 26338334
  73. TSen is a useful tool for unraveling the mechanisms underlying the spatiotemporal activation of TACE in live cells. PMID: 25714465
  74. The expression of mature ADAM10, ADAM17, and cleaved Notch 1 proteins in ARPE/EBV cells was downregulated after treatment with sorafenib through the regulatory activity of nardilysin (NRD-1). PMID: 26244291
  75. Results show that miR-145 inhibits liver cancer cell proliferation by directly targeting ADAM17. PMID: 25174729
  76. Data suggest secreted FRP3 (frizzled related protein-3) interacts with ADAM17 (A disintegrin/metalloprotease 17) substrate IL6R (interleukin-6 receptor) release; this interaction is down-regulated in osteoarthritis due to rare double variant in FRP3. PMID: 25846075
  77. we found a significant correlation between plasma TACE activity and CSF t-tau and Abeta42 levels and CSF Abeta42/tau ratios in Alzheimer disease and mild cognitive impairment. PMID: 24685635
  78. ADAM17 mRNA expression in esophageal squamous cell carcinoma was correlated with lymph node metastasis and tumor, node and metastasis staging. PMID: 25351873
  79. Human NOTCH2 but not mouse Notch2 is resistant to negative regulatory region perturbation and ligand-independent activation by Adam17. PMID: 25918160
  80. the intima+media of IPAH vessels, collagens (COL4A5, COL14A1, and COL18A1), matrix metalloproteinase (MMP) 19, and a disintegrin and metalloprotease (ADAM) 33 were higher expressed, whereas MMP10, ADAM17, TIMP1, and TIMP3 were less abundant. PMID: 25840998
  81. Postulate that the interaction of ADAM17 with CD13 and its downregulation following CD13 engagement has important implications in acute myeloid leukemia cells. PMID: 25246708
  82. Combining detection of plasma Notch1 and TACE may be reliable for identifying the presence of abdominal aortic aneurysms PMID: 25744398
  83. upregulation of ADAM17 was associated with microvascular invasion of cancer cells in HCC PMID: 24969373
  84. ADAM17 promoter polymorphism is associated with ischemic stroke. PMID: 24727681
  85. that both ADAM10 and ADAM17 are associated with FasL-containing secretory lysosomes. PMID: 25745808
  86. ADAM17 induction down-regulates the receptor in an irreversible manner and may serve as a master switch in controlling CXCR2 function. PMID: 25412626
  87. The ADAM17 identifies a role for ADAM17 in the pathophysiology of AAA and has important clinical implications with regard to potential therapeutics. PMID: 24853957
  88. LL-37 induced TACE and EGFR activation, as well as TGF-alpha and MUC5AC mucin production by NCI-H292 cells. PMID: 24901072
  89. APP regulates migration and ADAM10/ADAM17 gene expression in prostate cancer cells. PMID: 25218471
  90. Tylosis with oesophageal cancer-associated mutations in iRHOM2 cause an increase in the maturation and activity of ADAM17 in epidermal keratinocytes. PMID: 24643277
  91. transmembrane proteins can be released by two distinct mechanisms and point to a crucial role for ADAM17 in shaping the secretory profile of senescent cells PMID: 25077560
  92. ADAM17 RNAi decreased EMMPRIN, p-EGFR, p-ERK, MMP-2, and MMP-9 proteins in SiHa and HeLa cells PMID: 24793016
  93. It reported loss-of-function mutations in the human ADAM17 gene, encoding for the 'sheddase' ADAM17, a transmembrane protein which cleaves extracellular domains of substrate proteins including TNF-alpha, growth factors and desmoglein (DSG) 2. PMID: 24738885
  94. We showed that ADAM17 inhibitor upregulated chemokines in keratinocytes. PMID: 23786710
  95. Keratinocytes express ADAM17 during wound healing. PMID: 23834487
  96. Down-regulation of TIMP3 leads to increase in TACE expression and TNF-alpha production by placental trophoblast cells. PMID: 24495020
  97. ADAM17 is an important regulator of the tumorigenic properties of human NSCLC and may be used as a potential anticancer therapeutic target in NSCLC. PMID: 24626788
  98. Exosomes from HIV-1-infected cells induce quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. PMID: 25056899
  99. identified the region in IL-6R that binds to CANDIS. In contrast to the type I transmembrane proteins, the IL-6R, and IL-1RII, CANDIS does not bind the type II transmembrane protein TNF-alpha, demonstrating differences in the respective shedding by ADAM17 PMID: 24790088
  100. Studied the splicing variants of ADAM12 (L and S) and ADAM17 gene expression in melanoma at transcriptional and translational level in comparison with control (non-tumor) tissues. PMID: 23645517

Show More

Hide All

Involvement in disease Inflammatory skin and bowel disease, neonatal, 1 (NISBD1)
Subcellular Location Membrane, Single-pass type I membrane protein
Tissue Specificity Ubiquitously expressed. Expressed at highest levels in adult heart, placenta, skeletal muscle, pancreas, spleen, thymus, prostate, testes, ovary and small intestine, and in fetal brain, lung, liver and kidney.
Database Links

HGNC: 195

OMIM: 603639

KEGG: hsa:6868

STRING: 9606.ENSP00000309968

UniGene: Hs.404914

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1